In This Issue

KRAS G12C -mutant non-small cell lung cancer (NSCLC) presents a significant challenge in cancer treatment due to the rapid onset of resistance to targeted therapies.Although KRAS G12C inhibitors, like sotorasib, show initial clinical success, patients often experience adaptive resistance, meaning the cancer becomes less responsive to treatment, limiting long-term effectiveness.To address this challenge, researchers explored combining sotorasib with napabucasin, a drug that inhibits STAT3, a protein involved in cancer survival and immune suppression.Through high-throughput screening of 423 compounds, the researchers identified that napabucasin worked synergistically with sotorasib to suppress tumor growth in both sensitive and drug-resistant KRAS G12C -mutant NSCLC cell lines.Functional assays demonstrated that the combination not only enhanced tumor growth inhibition but also promoted the activation and infiltration of natural killer (NK) cells within the tumor.NK cells play a crucial role in the body's immune defense against cancer, and their activation is critical for effective tumor clearance.At a molecular level, the study revealed that blocking KRAS G12C unexpectedly activated STAT3, which helps tumors resist treatment by weakening the immune system.Napabucasin counteracted this effect by preventing STAT3 from binding to HLA-B, a gene that produces signals inhibiting NK cell activity.By reducing these signals, napabucasin enhanced NK cell function, making the immune system more effective at attacking tumors.This research sheds light on an important mechanism of adaptive resistance to KRAS G12C inhibitors, demonstrating that STAT3 activation supports tumor regrowth under KRAS inhibition.By blocking STAT3 and the associated suppression of NK cell activity, the study offers a new combination therapy approach that not only targets the cancer cells more effectively but also boosts the immune system's ability to fight the tumor.These findings provide strong evidence that combining KRAS G12C and STAT3 inhibitors could represent a promising strategy to improve treatment responses and overcome resistance in KRAS G12C -mutant NSCLC.